All-trans retinoic acid (ATRA), a targeted drug used to treat hematological malignancies, can inhibit cell proliferation in telomerase reverse transcriptase (TERT)-hypomethylated OC tissue types, and ATRA may be a new and effective individualized therapy [105]. Here, TERT is linked to hematologic disorder.